Product Program year 2025 Source: CMS Open Payments

Botox

Biological Urology

NDC 0023-1145-01

Open in the dashboard

General payments

$2,341,252

16,486 payments

Research payments

$70,155

10 payments

Through program year 2025, $2,341,252 in general payments and $70,155 in research payments were reported against Botox (Urology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2025 General $462,885 2,654
2024 General $436,226 1,849
2023 General $454,174 4,679
2023 Research $3,125 3
2022 General $469,362 5,115
2022 Research $30,000 1
2021 General $518,605 2,189
2021 Research $37,030 6

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,752,598 13,924 payments
  2. Allergan Inc. $588,654 2,562 payments
Top recipients General payments · program year 2025
  1. Steven Bernstein Urology · Edina, MN $63,438 14% · 99 payments
  2. Michael Kennelly Urology · Charlotte, NC $36,650 8% · 33 payments
  3. Karyn Eilber Urology · Santa Monica, CA $28,495 6% · 32 payments
  4. Daniel Gruber Urogynecology and Reconstructive Pelvic Surgery · Bethesda, MD $23,171 5% · 38 payments
  5. Laura Giusto Urology · Owings Mills, MD $22,007 5% · 28 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Urology $268,855 58% · 608 practitioners
  2. Urogynecology and Reconstructive Pelvic Surgery Obstetrics & Gynecology $77,963 17% · 80 practitioners
  3. Urogynecology and Reconstructive Pelvic Surgery Urology $60,884 13% · 26 practitioners
  4. Physician Assistant $15,637 3% · 144 practitioners
  5. Physician Assistant, Medical Physician Assistant $13,333 3% · 28 practitioners

The top 5 of 27 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $67,040 14% · 190 recipients
  2. Minnesota $64,420 14% · 43 recipients
  3. Maryland $46,735 10% · 34 recipients
  4. North Carolina $42,296 9% · 117 recipients
  5. New York $38,552 8% · 20 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

71,233

Prescriptions dispensed, refills included

Drug cost

$98,448,340

Paid at the pharmacy, in all

Prescribers

2,055

With 11 or more claims of it

Medicare Part D drugs matched to BOTOX, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Botox Onabotulinumtoxina Same name 2,055 71,233 $98,448,340

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Warren Spinner Neurology NY 478 $630,804 $50,524
Christina Kwasnica Physical Medicine and Rehabilitation AZ 343 $824,941 $1,457
Jay Mahajan Neurology NV 339 $536,635 $289
Stuart Hetrick Neurology AZ 320 $444,778 None on record
Hamid Sami Neurology CT 305 $442,480 $150

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to BOTOX
Billing code Providers Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 3,723 46,383,230 $225,551,789

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

16,486 general · 10 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record